What 4 Analyst Ratings Have To Say About Reata Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 4 analysts have published their opinion on Reata Pharmaceuticals (NASDAQ:RETA) stock, with 1 bullish and 3 somewhat bullish ratings. The company has an average 12-month price target of $116.5, which has increased by 17.68% over the past month.

June 12, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reata Pharmaceuticals has received 1 bullish and 3 somewhat bullish ratings from 4 analysts in the past 3 months. The average 12-month price target is $116.5, up 17.68% from the previous month.
The positive analyst ratings and the increase in the average 12-month price target over the past month indicate a bullish sentiment towards Reata Pharmaceuticals. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100